Synergistic weight loss and diabetes resolution with exenatide administration after laparoscopic gastric banding

Surgery for Obesity and Related Diseases

Volumn 5, Issue 1, 2009, Pages 128-131

  Rothkopf, Michael M ^a   Bilof, Michael L ^b   Haverstick, Lisa P ^c   Nusbaum, Michael J ^d  

^a The Metabolic Medicine and Weight Control Center   (United States)

^b Garden State Bariatrics and Wellness Center   (United States)

^c South Mountain Medical Consultants   (United States)

^d Obesity Treatment Centers of New Jersey   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; HEMOGLOBIN A1C; METFORMIN; PRAMLINTIDE; REPAGLINIDE;

ADULT; AEROBIC EXERCISE; ARTICLE; BLOOD GLUCOSE MONITORING; CASE REPORT; DIABETES MELLITUS; DIABETIC NEUROPATHY; DRUG DOSE INCREASE; FOLLOW UP; GASTRIC BANDING; GLYCEMIC CONTROL; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LOW CARBOHYDRATE DIET; MALE; OBESITY; PRIORITY JOURNAL; WEIGHT REDUCTION;

DIABETES MELLITUS, TYPE 2; GASTROPLASTY; HUMANS; HYPOGLYCEMIC AGENTS; LAPAROSCOPY; MALE; MIDDLE AGED; OBESITY, MORBID; PEPTIDES; VENOMS; WEIGHT LOSS;

EID: 58249090785     PISSN: 15507289     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soard.2008.09.005     Document Type: Article

References (26)

1. Dixon J.B., Obrien P.E., Playfair J., et al. Adjustable gastric banding and conventional therapy for type 2 diabetes. JAMA 299 (2008) 316-323
2. Buchwald H., Avidor Y., Braunwald E., et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 292 (2004) 1724-1737
3. Cummings D.E., Overduin J., Foster-Shubert K.E., and Carlson M.J. Role of the bypassed intestine in the anti-diabetic effects of bariatric surgery. Surg Obes Relat Dis 3 (2007) 109-115
4. Laferrère B., Heshka S., Wang K., et al. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care 30 (2007) 1709-1716
5. Cummings D.E., Overduin J., and Foster-Schubert K.E. Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution. J Clin Endocrinol Metab 89 (2004) 2608-2615
6. Rubino F., and Gagner M. Potential of surgery for curing type 2 diabetes mellitus. Ann Surg 236 (2002) 554-559
7. Korner J., Bessler M., Inabnet W., Taveras C., and Holst J.J. Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surg Obes Related Dis 3 (2007) 597-601
8. Dengelb D.R., Kelly A.S., Olson T.P., Kaiser D.R., Dengel J.L., and Bank A.J. Effects of weight loss on insulin sensitivity and arterial stiffness in overweight adults. Metabolism 55 (2006) 907-911
9. Unger R.H. Glucagon physiology and pathophysiology. N Engl J Med 285 (1971) 443-449
10. Mitrakou A., Kelley D., Mokan M., et al. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 326 (1992) 22-29
11. Muller W.A., Faloona G.R., Aguilar-Parada E., and Unger R.H. Abnormal alpha cell function in diabetes. N Engl J Med 283 (1970) 109-115
12. Rubino F., Gagner M., Gentileschi P., et al. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg 240 (2004) 236-242
13. Todd J.F., and Bloom S.R. Incretins and other peptides in the treatment of diabetes. Diabetic Med 24 (2007) 223-232
14. Raufman J.P. Bioactive peptides from lizard venoms. Regul Pept 61 (1996) 1-18
15. Edwards C.M.P., Stanley S.A., Davis R., et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 281 (2001) E155-E161
16. Buse J.B., Henry R.R., Han J., Kim D.D., Fineman M.S., and Baron A.D. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27 (2004) 2628-2635
17. DeFronzo R.A., Ratner R.E., Han J., Kim D.D., Fineman M.S., and Baron A.D. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28 (2005) 1092-1100
18. Kendall D.M., Riddle M.C., Rosenstock J., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28 (2005) 1083-1091
19. Blonde L., Han J., Mac S., Poon T., Taylor K., and Kim D. Exenatide reduced A1C and weight over 82 weeks in overweight patients with type 2 diabetes. [Abstract]. Diabetes 54 Suppl 1 (2005) A118
20. Nijhuis J., van Dielen F.M.H., Buurman W.A., and Greve J.W.M. Ghrelin, leptin and insulin levels after restrictive surgery: a 2-year follow-up study. Obes Surg 14 (2004) 783-787
21. Deitel M., Sidhu P., and Stone E. Effect of vertical banded gastroplasty on diabetes in the morbidly obese. Obes Surg 1 (1991) 113-114
22. Jensen K., Mason E., and Scott D. Changes in the postoperative hypoglycemic and antihypertensive medication requirements in morbidly obese diabetic patients after vertical banded gastroplasty. (abstract). Obes Surg 1 (1991) 114
23. Neve H., Soulsby C., Whiteley G., et al. Resolution of diabetes following vertical gastroplasty in morbidly obese patients. Obes Surg 3 (1993) 75-78
24. Parikh M., Ayoung-Chee P., Romanos E., et al. Comparison of rates of resolution of diabetes mellitus after gastric banding, gastric bypass, and biliopancreatic diversion. J Am Coll Surg 205 (2007) 631-635
25. Dolan K., Bryant R., and Fielding G. Treating diabetes in the morbidly obese by laparoscopic gastric banding. Obes Surg 13 (2003) 439-3
26. Little T.J., Pilichiewicz A.N., Russo A., et al. Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses. J Clin Endocrinol Metab 91 (2006) 1916-1923